The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treat…

Breast CancerMetastatic Triple-Negative Breast Cancer

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05570253

Phase 1

Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-ne…

Metastatic Triple-Negative Breast Cancer

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07011654

Phase 1

Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer

This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed do…

Metastatic Triple-negative Breast Cancer

~Estimated

~$10 – $6,250

Yale UniversityNCT06963905